How Low Can You Go? The Radiobiology of Hypofractionation

被引：24
作者：
Brand, D. H. [1 ]
Kirby, A. M. [1 ,2 ]
Yarnold, J. R. [1 ,2 ]
Somaiah, N. [1 ,2 ]
机构：
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
CLINICAL ONCOLOGY | 2022年 / 34卷 / 05期
关键词：
Hypofractionation; radiobiology; BODY RADIATION-THERAPY; EARLY BREAST-CANCER; CONVENTIONAL RADIOTHERAPY; STEREOTACTIC BODY; FRACTIONATED RADIOTHERAPY; NON-INFERIORITY; FAST-FORWARD; HUMAN-SKIN; SENSITIVITY; TOXICITY;
D O I：
10.1016/j.clon.2022.02.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypo fractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue. (C) 2022 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码：280 / 287
页数：8
相关论文
共 63 条
  • [1] On the Sensitivity of α/β Prediction to Dose Calculation Methodology in Prostate Brachytherapy
    Afsharpour, Hossein
    Walsh, Sean
    Fekete, Charles-Antoine Collins
    Vigneault, Eric
    Verhaegen, Frank
    Beaulieu, Luc
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 345 - 350
  • [2] Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
    Ahmed, Kamran A.
    Liveringhouse, Casey L.
    Mills, Matthew N.
    Figura, Nicholas B.
    Grass, G. Daniel
    Washington, Iman R.
    Harris, Eleanor E.
    Czerniecki, Brian J.
    Blumencranz, Peter W.
    Eschrich, Steven A.
    Scott, Jacob G.
    Diaz, Roberto
    Torres-Roca, Javier F.
    [J]. EBIOMEDICINE, 2019, 47 : 163 - 169
  • [3] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Alemayehu, Wendimagegn Ghidey
    Heemsbergen, Wilma
    Heijmen, Ben
    Incrocci, Luca
    [J]. LANCET ONCOLOGY, 2016, 17 (04) : 464 - 474
  • [4] TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
    Anbalagan, Selvakumar
    Stroem, Cecilia
    Downs, Jessica A.
    Jeggo, Penny A.
    McBay, David
    Wilkins, Anna
    Rothkamm, Kai
    Harrington, Kevin J.
    Yarnold, John R.
    Somaiah, Navita
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
    Ball, David
    Mai, G. Tao
    Vinod, Shalini
    Babington, Scott
    Ruben, Jeremy
    Kron, Tomas
    Chesson, Brent
    Herschtal, Alan
    Vanevski, Marijana
    Rezo, Angela
    Elder, Christine
    Skala, Marketa
    Wirth, Andrew
    Wheeler, Greg
    Lim, Adeline
    Shaw, Mark
    Schofield, Penelope
    Irving, Louis
    Solomon, Benjamin
    [J]. LANCET ONCOLOGY, 2019, 20 (04) : 494 - 503
  • [6] Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer
    Bentzen, SM
    Saunders, MI
    Dische, S
    [J]. RADIOTHERAPY AND ONCOLOGY, 1999, 53 (03) : 219 - 226
  • [7] Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
    Brand, Douglas H.
    Bruningk, Sarah C.
    Wilkins, Anna
    Fernandez, Katie
    Naismith, Olivia
    Gao, Annie
    Syndikus, Isabel
    Dearnaley, David P.
    Tree, Alison C.
    van As, Nicholas
    Hall, Emma
    Gulliford, Sarah
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (02): : 596 - 608
  • [8] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
    Brand, Douglas H.
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Henderson, Daniel
    Brown, Stephanie
    Cruickshank, Clare
    Burnett, Stephanie
    Duffton, Aileen
    Griffin, Clare
    Hinder, Victoria
    Morrison, Kirsty
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    [J]. LANCET ONCOLOGY, 2019, 20 (11) : 1531 - 1543
  • [9] Fractionation and late rectal toxicity
    Brenner, DJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04): : 1013 - 1015
  • [10] Bristol, BRISTOL MYERS SQUIBB
1234567